TY - JOUR T1 - COVID-19 in Children with Brain-Based Developmental Disabilities: A Rapid Review JF - medRxiv DO - 10.1101/2020.05.01.20088021 SP - 2020.05.01.20088021 AU - Michèle Dugas AU - Valérie Carnovale AU - Andrée-Anne Poirier AU - Benoit Mailhot AU - Becky Skidmore AU - Lena Faust AU - Carrie Costello AU - Donna Thomson AU - Annette Majnemer AU - Dan Goldowitz AU - Steven P. Miller AU - Annie LeBlanc Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/06/2020.05.01.20088021.abstract N2 - Background The prevalence of symptomatic COVID-19 in children remains low to date. In just a few months, COVID-19 has affected millions of people worldwide, and as of the date of this publication, the pandemic continues. Based on the current available evidence, children do not appear to be at higher risk of contracting COVID-19 than adults. However, children with neurological and neuromuscular conditions are vulnerable to the respiratory complications of other viral infections.Objectives To assess whether children with brain-based developmental disabilities were more likely to develop COVID-19 and have complications or poorer outcomes following infection.Methods We conducted a two-week rapid review on studies with primary data regarding children aged between zero and 18 years old with brain-based developmental disabilities, or who were at risk of developing such disabilities, with confirmed or suspected COVID-19. We performed our literature searches on April 18, 2020.Results Our search strategy identified 538 individual records, of which four were included in our review. Of the 50 COVID-19 pediatric patients reported in the included studies, a total of seven children were at risk of developing brain-based disabilities. Symptoms ranged in severity. However, generally, patients were discharged or saw improvements in their symptoms by the end of the study period. No deaths were reported.Discussion Our study highlights a knowledge gap regarding the impact of COVID-19 in children with brain-based developmental disabilities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis review was funded by the CHILD-BRIGHT Network and the SPOR Evidence Alliance. Both Networks are supported by the Canadian Institutes of Health Research under Canada’s Strategy for Patient-Oriented Research (SPOR) Initiative.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request to the corresponding author. ER -